Background--Microparticles (MPs) are circulating membrane particles of less than a micrometer in diameter shed from endothelial and blood cells. Recent literature suggests that MPs are not just functionally inert cell debris but may possess biological functions and mediate the communication between vascular cells. As a significant proportion of MPs originate from platelets and endothelial cells, we hypothesized that MPs may harbor functional enzymes including an endothelial NO synthase (eNOS).
M icroparticles (MPs) are shed membrane particles of less than a micrometer in diameter thought to be budded into the circulation from endothelial cells and various blood cells, including platelets, leukocytes, and erythrocytes. [1] [2] [3] Thus, circulating MPs constitute a heterogeneous population of different cellular origins, numbers, size, and antigenic composition. Proposed mechanisms of MP generation include apoptosis and cellular activation by cytokines. [1] [2] [3] MPs circulate in blood from healthy individuals, and their numbers are increased in several cardiovascular diseases and conditions that predispose to cardiovascular disease. [1] [2] [3] MPs have long been considered functionally inert cell debris, and the number of circulating MPs in blood was proposed to be a marker of endothelial damage and platelet activation. 1, 3 More recently, it was appreciated that MPs harbor a number of membrane and cytoplasmatic proteins from the cells they originate from [4] [5] [6] and, therefore, may play a role as a disseminated storage pool of bioactive effectors in intercellular communication mediating effects in cardiovascular physiology and pathophysiology. [1] [2] [3] 7, 8 The enzyme endothelial nitric oxide synthase (eNOS) and its product nitric oxide (NO) play a central role in the control of vascular homeostasis. 9 ,10 A significant proportion of circulating MPs originate from platelets and endothelial cells, which both express eNOS. We hypothesized that MPs may harbor a functional eNOS. Therefore, we analyzed eNOS expression and activity in MPs isolated from healthy individuals, as well as from patients with cardiovascular disease, a condition characterized by impaired eNOS activity and/or expression.
Methods Human Volunteers
Blood was taken from the cubital veins of healthy human volunteers and cardiovascular disease (CVD) patients with documented endothelial dysfunction ( Table 1 ). All subjects gave written informed consent. Procedures were conducted in conformity with the principle embodied in the Declaration of Helsinki and approved by the ethics committee of the Heinrich Heine University. Inclusion was based on a diagnosis of coronary artery disease (CAD), defined as >70% stenosis of ≥1 coronary artery. Exclusion criteria consisted of the presence of heart rhythms other than sinus rhythm, clinical diagnosis of heart failure (NYHA III or IV), recent or current inflammatory condition, renal insufficiency (GFR <60 mL/min), active malignancies within the last year, pre-or perimenopausal state, documented noncompliance with medication, and active smoking (>1 cigarette/day).
Materials
Fluoresceine isothiocyanate (FITC)-conjugated monoclonal mouse anti-human CD235 (glycoforin) antibody was purchased from Miltenyi Biotech (Bergisch Gladbach, Germany), PE-conjugated mouse anti-human CD62E came from Beckton Dickinson Pharmingen (Heidelberg, Germany). FITC-conjugated monoclonal mouse anti-human CD45 antibody, PC5-conjugated mouse anti-human CD41, and PEconjugated mouse anti-human CD144 antibodies and FlowCount fluorospheres were from Beckman Coulter (Krefeld, Germany). Materials for immunoprecipitation, gel electrophoresis, and Western blots were purchased from Invitrogen (Darmstatdt, Germany). Purified monoclonal mouse anti-human eNOS and purified rabbit anti-eNOS antiserum were from BD Bioscience (Erembodegem, Belgium). We also used a mouse monoclonal anti-eNOS (clone NOS-E1) from Sigma (Deisenhofen, Germany) and phenazine methosulfate (PMS) from Biomol (Enzo Lifescience). L-N 5 -(1-iminoethyl)-ornithine (L-NIO) and N G -nitro-L-arginine-methyl ester monohydrochloride (L-NAME)
were from Alexis Biochemicals (Loerrach, Germany 
Blood Collection and Preparation of Platelet-Rich Plasma and Platelet-Free Plasma
Citrated blood (6 mL) was drawn from the cubital vein and processed within 2 hours. Platelet-rich plasma (PRP) was 
Immunoprecipiatation and Western Blot Analysis
An MP pellet from each individual was lysed by sonication at 4°C and resuspended in 0.2 mL lysis buffer with protease inhibitors (25 mmol/L Tris-HCl, 150 mmol/L NaCl, 1 mmol/L phenylmethanesulfonyl fluoride, 1 mg/mL aprotinin, 10 mg/ mL leupeptin, 1 mmol/L EDTA, 50 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1% Triton-X [pH 7.6]). Protein concentration was measured using a Biorad DC protein assay kit (Biorad, Munich, Germany). For immunoprecipitation MP lysate (30 lg/lL protein) was incubated for 1 hour at RT with 40 lg of a mouse anti-human eNOS antibody (BD Bioscience). Immune complexes were isolated by magnetic separation using 50 lL of washed magnetic protein G Dynabeads prepared as recommended by the manufacturer (Invitrogen). Western blot was performed as previously described. 13 Briefly, 30 lg of MP lysate or the immunocomplexes eluted from the magnetic beads were loaded on 10% NuPAGE Novex Tris/Acetate precast gels (Invitrogen). To control for contamination of plasma proteins in MP preparations, 30 lg of MP-free plasma (see above) was also loaded into the gels. As reference and normalization of band intensity, we loaded equal amounts (30 lg) of the same human umbilical endothelial cells (HUVECs) lysate in all gels. HUVECs were cultured as described previously. 14 Proteins
were transferred onto PVDF membrane Hybond P (Amersham Biosciences, Munich, Germany). The membrane was stained with a rabbit anti-eNOS antiserum (1:1000; BD Bioscience) or mouse monoclonal anti-human eNOS antibody (Sigma Aldrich, Munich, Germany) and with a secondary HRP-conjugated goat anti-rabbit or anti-mouse antibody, respectively (1:5000; Rockland, PA 
In all experiments, recombinant bovine eNOS was used as a positive control. The concentration of nitrite as the product of NO oxidation was measured by chemiluminescence. 16 
Analysis of NO Levels by Laser-Scanning Microscopy and Flow Cytometry
Intracellular NO levels were detected by staining MPs with MNIP, which was coordinated with Cu(II) to form a stable coordination compound, MNIP-Cu. 17 MNIP-Cu is a cellpermeable fluorescent probe that reacts rapidly and specifically with NO to generate a blue fluorescence. MNIP was synthesized as previously described. 11 Stock solutions of MNIP-Cu were prepared by mixing 1 volume of MNIP (1 mmol/L in dimethyl sulfoxide) and 2 volumes of CuSO 4 (2.5 mmol/L) and incubated for 30 minutes in the dark. First, intracellular NO levels were assessed by laserscanning microscopy. Platelet-poor plasma (PPP) was obtained as described for PFP but omitting the second centrifugation step. This led to platelet contamination that we used as a positive control in these experiments. To verify whether NO levels within the circulating MPs contain eNOS activity, PPP was pelleted by centrifugation preincubated with PBS as a control or with the NOS inhibitor L-NAME for 30 minutes at 37°C and then loaded with MNIP-Cu (10 lmol/L) for 15 minutes at RT in the dark. PPP smears were analyzed 1 to 2 minutes after preparation under a confocal laser-scanning microscope. Samples were excited with a UV laser enterprise, and emission was analyzed using a UV/488/543/ 633-nm beam splitter and a 350-nm long-pass filter. The platelets in the PPP served as a positive control, and MNIPCu-unloaded samples served as an autofluorescence control.
Second, intracellular NO levels were measured in intact MPs by flow cytometry. PFP was preincubated with PBS as a control or with the NOS inhibitor L-NAME for 30 minutes at 37°C and then loaded with MNIP-Cu (10 lmol/L) for 15 minutes at RT in the dark. Samples were analyzed immediately in a Canto II flow cytometer (Beckman Coulter). MNIP-Cu-unloaded samples served as an autofluorescence control.
Detection of Reactive Oxygen Species in MPs by Flow Cytometry
Intraparticular levels of reactive oxygen species (ROS) were measured by the staining of MPs with MitoSox and DCF 
Flow-Mediated Dilation
Endothelial function was assessed by measuring flow-mediated dilation of the brachial artery by ultrasound (Sonosite Micromax, Bothell, WA) in combination with an automated analysis system (Brachial Analyzer, Medical Imaging Applications, Iowa City, IO) in a 21°C temperature-controlled room as described previously. 12 
Statistical Analyses
Results are expressed as meanAEstandard error of the mean (SEM). Student t tests and repeated-measures analysis of variance (ANOVA) with the Bonferroni post hoc test were used to evaluate the significance of differences in the mean values between different samples when comparing 2 or >2 samples, respectively. Patient characteristics were analyzed using nonparametric the Mann-Whitney U test. P<0.05 was considered statistically significant when 2 groups were compared. To avoid inflation of the alpha level, significance levels were adjusted (Bonferroni) when multiple comparisons were computed by dividing the P value by the number of post hoc tests performed.
Results

Human Circulating MPs Carry an Endothelial Nitric Oxide Synthase
Removal of platelet contamination is crucial for proteomic analysis of circulating MPs in plasma. We purified MPs by sequential centrifugation of human plasma. Analysis of the different fractions by flow cytometry and laser-scanning microscopy revealed that PRP contained both platelets with a size >1 lm, ranging from 1.5 to 3 lm in diameter, and MPs with a size <1 lm ( Figure 1A ). PFP did not contain any platelets ( Figure 1B) . The major subpopulations of MPs ( Figure 1C ) were identified to be of platelet origin (CD41 + , 40%), closely followed by endothelial origin (CD41 À /CD31 + , 25%; CD144 + , 28%; CD62e + , 5%). Other subpopulations were erythrocyte-derived (CD235 + , 10%) and leukocyte-derived (CD45 + , 8%) MPs.
We found that MPs express an eNOS (Figure 2A) , as demonstrated by both immunoprecipitation of eNOS with a mouse monoclonal anti-eNOS antibody from PFP ( Figure 2A,  lane 1) or Western blot analysis of a crude MP lysate ( Figure 2A, lane 2). The same band at an approximate molecular weight of 135 kDa was also present in lysate from platelets and from human endothelial cells (Figure 2A, lanes 3+4 ). The specificity of the band was further confirmed by staining with a rabbit antieNOS antibody or a mouse monoclonal anti-eNOS antibody directed against different epitopes. No eNOS was detected in MP-free plasma (Figure 2A, bottom gel) . H]-citrulline production over time, which was inhibited by the addition of the specific NOS inhibitor L-NAME ( Figure 2B ). Ca .0125 compared with L-NAME (2B). C, NOS activity is inhibited by the NOS inhibitor L-NAME and by the Ca 2+ chelators EDTA and EGTA. D, NOS-dependent nitrite accumulation was substrate dependent (n=6). *P<0.025 compared with L-arginine only. P values represent Bonferroni-corrected significance levels. MPs indicates microparticles; eNOS, endothelial nitric oxide synthase; PRP, platelet-rich plasma; PFP, platelet-free plasma; HUVEC, human umbilical vein endothelial cell; MWM, molecular weight marker; L-NAME, N G -nitro-L-arginine-methyl ester monohydrochloride.
NOS activity was also determined by measuring NOSdependent nitrite accumulation in the presence of L-arginine and enzymatic cofactors. In the presence of L-arginine and Ca 2+ /calmodulin, the measured nitrite accumulation was 19.8AE1.8 nmol/L within 120 minutes of incubation. If the inactive substrate D-arginine was added instead of L-arginine or after the addition of the NOS inhibitor L-NAME, nitrite accumulation was significantly impaired (8.8AE1.6 and 11.6AE2.4 nmol/L, respectively; Figure 2D ). We also found that intact MPs produced NOS-derived NO. A significant increase in intraparticular fluorescence was achieved using a NO-specific membrane-permeable fluorescent probe (MNIP-Cu). The platelet contamination within PPP was used as a positive control in these experiments, as platelets are known to express an active eNOS producing NO. Laser-scanning microscopy revealed a blue fluorescence signal in MPs and platelets loaded with the NO probe MNIPCu ( Figure 3A, upper panels) . Pretreatment with the NOS inhibitor L-NAME significantly blunted fluorescent activity, comparable to the unloaded control MPs ( Figure 3A , middle panels). The same observations were confirmed by flow cytometry (Figure 3B and 3C) . Unloaded samples were analyzed to control for autofluorescence ( Figure 3A , bottom panel, and Figure 3B , first peak). as measured by laser-scanning microscopy (A) and flow cytometry (n=10; B+C). The addition of the specific NOS inhibitor L-NAME decreased fluorescence. Unloaded MPs (UL) were used as a control for autofluorescence. *P<0.05 compared with samples without L-NAME. NO indicates nitric oxide; MPs, microparticles; NOS, nitric oxide synthase; L-NAME, N G -nitro-L-arginine-methyl ester monohydrochloride; MNIP-Cu, 4-methoxy-
The total number of circulating MPs was increased in the plasma of CVD patients compared with healthy controls ( Figure 4B ). This was mainly driven by an increase in endothelial cell-and platelet-derived MPs. In a subgroup of the study population, we analyzed eNOS expression and activity (n=11, healthy; n=7, CAD). In MPs circulating in the plasma of CVD patients, we detected significantly reduced levels of eNOS protein ( Figure 4C ) compared with in healthy volunteers. Figure 4D shows the densitometric analysis. Band intensity was normalized for the intensity of the eNOS band in HUVECs. Equal loading was confirmed by staining a duplicate gel with Coomassie Brilliant Blue.
Of interest, the NOS-dependent conversion of as also demonstrated by the lack of a measurable effect of the NOS inhibitor L-NAME.
We also compared superoxide generation in MPs from the patients with cardiovascular diseases and from healthy volunteers. Our data showed that the mean fluorescence intensity of MitoSox, a probe for O 2 À , as well as of DCF, a probe for ROS, measured by flow cytometry, did not significantly differ between the groups ( Figure 4F ). As a positive control, we treated MPs with O 2 À or with H 2 O 2 . This strongly increased intracellular fluorescence activity of MitoSox as well as of DCF. The addition of EUK 134, a cell membrane-permeable ROS scavenger, decreased the intracellular fluorescence activity of Mitosox and DCF ( Figure 5 ). In summary, our data suggest that the decrease in NOS activity was mainly a result of decreased protein levels in MPs from CVD patients compared with healthy individuals, whereas ROS levels were unchanged.
Discussion
We have demonstrated that circulating MPs express an active eNOS and produce NO. In patients with cardiovascular diseases, impaired endothelium-dependent vasodilation was associated with decreased eNOS expression and activity in circulating MPs. Taken together, our data support the concept that MPs may not only retain phenotypic markers but also preserve the expression and functionality of enzymes of the cells they originate from, including eNOS, and may mediate and transport their physiological functions. In cardiovascular disease, an increase in endothelium-derived MP subpopulations accompanied by a decrease in MPs' eNOS activity may not merely be an index of a dysfunctional endothelium, but may also contribute to disturbed NO bioavailability and hence play a role in the pathophysiology of cardiovascular disease.
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